Sonova Holding AG

Sonova Holding is a hearing instrument manufacturer based in Switzerland. Co. specializes in the design, development, manufacture, and worldwide distribution of technologically advanced wireless and hearing systems for adults and children with hearing impairment. Co. offers a range of digital hearing instruments, along with high tech specialty products and complementary wireless communications systems. Co. comprises two hearing instrument divisions, Phonak and Unitron Hearing, as well as Phonak Communications, a developer of wireless communication devices for both hearing instrument and other applications.
  • TickerPHBN
  • ISINCH0012549785
  • ExchangeSix Swiss Exchange
  • SectorHealth Care Equipment & Services
  • CountrySwitzerland

Analysts

SONOVA HOLDING AG sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of SONOVA HOLDING AG (CH), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 8, 2019, the closing price was CHF 190.55 and its potential was estimated at CHF 205.17.

Sonova – Proxinvest Corporate Governance Rating ® : B

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

1 director sold after exercising options/sold

A director at Sonova Holding Ag sold after exercising options/sold 9,283 shares at 0.000CHF and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under list...

Alex Morozov

Morningstar | Much of Sonova's Near Term Depends on Its Latest Launch of Marvel Platform

Sonova benefits from favorable trends, including an aging population, increasing noise pollution, fairly low penetration rates for hearing aids in the developed world, and virtually untapped patient populations in emerging markets. Its broad product offerings should allow the company to capitalize on these trends, while its strong brand and superior technological know-how should yield market share gains.Sonova controls about a fourth of the world's hearing aid market, roughly in line with its key competitor, William Demant. The two rivals are very similar in their approach to the market. Both ...

Alex Morozov

Much of Sonova's Near Term Depends on Its Latest Launch of Marvel Platform

Sonova's first-half results were below our expectations, albeit much of the weakness was due to purchase deferrals ahead of the new product introduction launched this month. We are maintaining our fair value estimate for now, as the modest downward revision to our full-year forecast is largely offset by cash flows realized since our last report. There is, however, a greater uncertainty baked into our 2019 numbers, with volume and pricing highly contingent on the success of Phonak Marvel. We main...

Alex Morozov

Morningstar | Much of Sonova's Near Term Depends on Its Latest Launch of Marvel Platform

Sonova benefits from favorable trends, including an aging population, increasing noise pollution, fairly low penetration rates for hearing aids in the developed world, and virtually untapped patient populations in emerging markets. Its broad product offerings should allow the company to capitalize on these trends, while its strong brand and superior technological know-how should yield market share gains.Sonova controls about a fourth of the world's hearing aid market, roughly in line with its key competitor, William Demant. The two rivals are very similar in their approach to the market. Both ...

Alex Morozov

Much of Sonova's Near Term Depends on Its Latest Launch of Marvel Platform

Sonova's first-half results were below our expectations, albeit much of the weakness was due to purchase deferrals ahead of the new product introduction launched this month. We are maintaining our fair value estimate for now, as the modest downward revision to our full-year forecast is largely offset by cash flows realized since our last report. There is, however, a greater uncertainty baked into our 2019 numbers, with volume and pricing highly contingent on the success of Phonak Marvel. We main...

Alex Morozov

Morningstar | Sonova's First-Half Results Slightly Weaker Than Expected; Pipeline Looks Improved

Sonova's first-half results were below our expectations, albeit much of the weakness was due to purchase deferrals ahead of the new product introduction launched this month. We are maintaining our fair value estimate for now, as the modest downward revision to our full-year forecast is largely offset by cash flows realized since our last report. There is, however, a greater uncertainty baked into our 2019 numbers, with volume and pricing highly contingent on the success of Phonak Marvel. We maintain our narrow-moat rating. Group sales were up a modest 2.6% in local currency, with demand in th...

Alex Morozov

Sonova's First-Half Results Slightly Weaker Than Expected; Pipeline Looks Improved

Sonova's first-half results were below our expectations, albeit much of the weakness was due to purchase deferrals ahead of the new product introduction launched this month. We are maintaining our fair value estimate for now, as the modest downward revision to our full-year forecast is largely offset by cash flows realized since our last report. There is, however, a greater uncertainty baked into our 2019 numbers, with volume and pricing highly contingent on the success of Phonak Marvel. We main...

Alex Morozov

Morningstar | We Don't See FDA Approval of First Direct-to-Consumer Device as a Threat to the Hearing Aid Industry

We saw share prices tumble this week for publicly traded hearing aid manufacturers Sonova, William Demant, and GN, following the announcement by the U.S. Food and Drug Administration late last week that it would allow commercialisation of hearing "aids" manufactured by Bose directly to the consumer, bypassing professional audiologists. This isn't a particularly surprising development. Ever since the U.S. Congress' passage of the Over-the-Counter Hearing Aid Act in 2017, we've been anticipating an entrant in this category; Bose being the one makes sense, given the company's premium brand positi...

1 director sold after exercising options/sold

A director at Sonova Holding Ag sold after exercising options/sold 9,283 shares at 0.000CHF and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under list...

SONOVA HOLDING AG sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of SONOVA HOLDING AG (CH), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date March 8, 2019, the closing price was CHF 190.55 and its potential was estimated at CHF 205.17.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Sonova – Proxinvest Corporate Governance Rating ® : B

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care outperforming globally -- overweight; India breaking out -- add exposure With the primary global ex-U.S. indexes MSCI EAFE, MSCI EM, and MSCI ACWI ex-U.S. continuing their sideways to downward consolidation from a price perspective, the importance of Sector, Group, and stock selection is critical. • Sector and Group Opportunities. Today we put the spotlight on the Health Care Sector, which is assuming a global leadership role as it separates itself from the other international Sectors. We also focus on the Communications Sector as it has seen steady relative strength ranking (RSR...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch